Free Trial

GeneDx (NASDAQ:WGS) Coverage Initiated by Analysts at Piper Sandler

GeneDx logo with Medical background

Equities research analysts at Piper Sandler started coverage on shares of GeneDx (NASDAQ:WGS - Get Free Report) in a research report issued on Wednesday, MarketBeat Ratings reports. The brokerage set an "overweight" rating and a $110.00 price target on the stock. Piper Sandler's target price suggests a potential upside of 19.72% from the company's current price.

A number of other brokerages also recently weighed in on WGS. Wells Fargo & Company cut their price target on shares of GeneDx from $105.00 to $78.00 and set an "equal weight" rating on the stock in a report on Thursday, May 1st. Guggenheim reiterated a "buy" rating and issued a $115.00 target price (up from $88.00) on shares of GeneDx in a research note on Monday, June 30th. TD Securities decreased their price target on shares of GeneDx from $135.00 to $110.00 and set a "buy" rating for the company in a research note on Thursday, May 1st. Jefferies Financial Group upgraded GeneDx from a "hold" rating to a "buy" rating and set a $80.00 price objective on the stock in a research note on Friday, May 9th. Finally, Wall Street Zen upgraded shares of GeneDx from a "hold" rating to a "buy" rating in a research note on Saturday. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $92.33.

Check Out Our Latest Research Report on WGS

GeneDx Stock Up 7.8%

Shares of WGS stock traded up $6.66 on Wednesday, hitting $91.88. The stock had a trading volume of 1,081,105 shares, compared to its average volume of 821,134. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.25 and a quick ratio of 3.07. The business has a 50 day moving average of $72.19 and a 200 day moving average of $82.51. GeneDx has a 12-month low of $25.32 and a 12-month high of $117.75. The stock has a market cap of $2.62 billion, a price-to-earnings ratio of -65.16 and a beta of 2.01.

GeneDx (NASDAQ:WGS - Get Free Report) last posted its earnings results on Wednesday, April 30th. The company reported $0.28 EPS for the quarter, topping the consensus estimate of $0.11 by $0.17. The firm had revenue of $87.12 million for the quarter, compared to analysts' expectations of $79.90 million. GeneDx had a negative net margin of 11.69% and a positive return on equity of 10.17%. As a group, analysts expect that GeneDx will post 0.97 EPS for the current year.

Insider Transactions at GeneDx

In related news, CFO Kevin Feeley sold 1,344 shares of the business's stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $91.12, for a total value of $122,465.28. Following the completion of the sale, the chief financial officer owned 7,425 shares in the company, valued at $676,566. The trade was a 15.33% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Keith A. Meister acquired 100,000 shares of the stock in a transaction on Thursday, May 8th. The shares were bought at an average price of $56.01 per share, with a total value of $5,601,000.00. Following the purchase, the director directly owned 3,008,629 shares of the company's stock, valued at $168,513,310.29. The trade was a 3.44% increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders sold 13,913 shares of company stock worth $1,314,514. 29.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Ameriprise Financial Inc. bought a new stake in shares of GeneDx in the fourth quarter worth approximately $2,645,000. Envestnet Asset Management Inc. purchased a new stake in GeneDx in the fourth quarter worth approximately $380,000. Prudential Financial Inc. bought a new stake in GeneDx in the 4th quarter worth approximately $7,938,000. Voya Investment Management LLC purchased a new stake in GeneDx during the 4th quarter valued at $292,000. Finally, GAMMA Investing LLC lifted its holdings in shares of GeneDx by 22,194.3% during the 1st quarter. GAMMA Investing LLC now owns 38,792 shares of the company's stock valued at $3,436,000 after buying an additional 38,618 shares during the period. Hedge funds and other institutional investors own 61.72% of the company's stock.

GeneDx Company Profile

(Get Free Report)

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.

Recommended Stories

Analyst Recommendations for GeneDx (NASDAQ:WGS)

Should You Invest $1,000 in GeneDx Right Now?

Before you consider GeneDx, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GeneDx wasn't on the list.

While GeneDx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines